DMPK Insights
DMPK Insights is a by-monthly podcast by Pharmaron about the latest research and developments in DMPK science with a focus on three different areas:- Current Considerations: Breaking DMPK science with a focus on recent scientific publications, regulatory and other considerations - Influential Individuals: Key DMPK scientific influencers – career path, research focus, future plans- Trending Technologies: Technological advances in DMPK science – what does it do and why is it needed?
DMPK Insights
DMPK Insights #13: The Influence of QSAR and Physicochemical Descriptors on Drug Design: A Brief History and New Paradigms
For a captioned version or to access the transcript, please visit: https://www.pharmaron.com/knowledge-center/dmpk-insights-13-qsar-physicochemical-descriptors/
In this podcast, Scott Summerfield and Matt Segall will discuss QSAR and how in silico ADME science has evolved to influence Drug Design and improve the ADME properties of hit and lead compounds.
We will address the following questions:
- What were the drivers for the emergence of QSAR and Phys Chem Descriptors?
- Today’s state-of-the art for ADME scientists to know about?
- How will QSAR is likely to evolve in the near future
Our Moderator:
Scott Summerfield – Executive Director Metabolism at Pharmaron
Scott Summerfield is the head of Metabolism, leading clinical and nonclinical radiolabeled ADME (Pharma and Environmental), in vivo support, imaging, as well as Discovery/Development and bioanalysis metabolite ID. Scott joined Pharmaron in 2022, having worked in the Pharmaceutical Industry for over 20 years, supporting both small and large molecule DMPK projects (Discovery and Development). He holds a PhD and a postdoctoral degree in protein mass spectrometry. He has published extensively in the areas of bioanalysis and the permeation of drugs across the blood-brain barrier.
Our Speaker:
Matt Segall – CEO at Optibrium
Matt Segall is the CEO of Optibrium. He holds a Master of Science in Computation from the University of Oxford and a Ph.D. in Theoretical Physics from the University of Cambridge. As Associate Director at Camitro (UK), ArQule Inc., and subsequently at Inpharmatica, he led a team in developing predictive ADME models and state-of-the-art, intuitive decision-support and visualization tools for drug discovery. In January 2006, he assumed responsibility for managing Inpharmatica’s ADME business, encompassing experimental ADME services and the StarDrop software platform. Following the acquisition of Inpharmatica, Matt became Senior Director responsible for BioFocus DPI’s ADMET division and, in 2009, led a management buyout of the StarDrop business to found Optibrium, which develops software and AI solutions for small molecule design, optimisation, and data analysis. Matt has published over 30 peer-reviewed papers and book chapters on computational chemistry, cheminformatics, and drug discovery.
Stay tuned for more podcasts in our Pharmaron DMPK Insights Series!